Bristol-Myers Squibb (NYSE:BMY) shares sold by American Century Companies Inc.

American Century Companies Inc. lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 8.2% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 2,593,428 shares of the biopharmaceutical company’s stock after selling 232,327 shares during the period. American Century Companies Inc. owned about 0.13% of Bristol-Myers Squibb worth $107,705,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of BMY. Gryphon Financial Partners LLC increased its stake in shares of Bristol-Myers Squibb by 23.5% during the fourth quarter. Gryphon Financial Partners LLC now owns 5,235 shares of the biopharmaceutical company’s stock worth $280,000 after purchasing an additional 995 shares during the period. Fiera Capital Corp purchased a new stake in Bristol-Myers Squibb during the fourth quarter valued at $508,000. Atlantic Edge Private Wealth Management LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at $67,000. Financial Advocates Investment Management raised its position in shares of Bristol-Myers Squibb by 10.1% in the fourth quarter. Financial Advocates Investment Management now owns 17,184 shares of the biopharmaceutical company’s stock worth $882,000 after acquiring an additional 1,576 shares during the period. Finally, Verity Asset Management Inc. raised its stake in shares of Bristol-Myers Squibb by 20.4% during the 4th quarter. Verity Asset Management Inc. now owns 5,897 shares of the biopharmaceutical company’s stock worth $303,000 after acquiring an additional 1,000 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s shares.

Bristol-Myers Squibb trading rose 1.8%

BMY opened at $49.13 on Friday. The company’s 50-day moving average price is $46.79 and its 200-day moving average price is $46.53. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02, and a current ratio of 1.16. The stock has a market cap of $99.61 billion, a PE ratio of -15.85, a P/E/G ratio of 12.59 and a beta of 0.46. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $60.55.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last announced its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.64 by $0.43. The business had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The company’s quarterly revenue was up 8.7% year over year. In the same quarter last year, the company posted EPS of $1.75. As a group, equities research analysts expect that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb announces dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, October 4. This represents an annualized dividend of $2.40 and a dividend yield of 4.88%. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

The Wall Street analyst weighs in

BMY has been the subject of several analyst reports. StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Deutsche Bank Aktiengesellschaft cut their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research note on Tuesday, July 23rd. TD Cowen boosted their target price on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a “hold” rating in a research note on Monday, August 12th. Cantor Fitzgerald restated a “neutral” rating and set a $45.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, July 22nd. Finally, Barclays upped their target price on Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an “underweight” rating in a report on Thursday, August 22nd. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $54.67, according to MarketBeat.com.

Get the latest analysis on Bristol-Myers Squibb

About Bristol-Myers Squibb

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured stories

Want to see what other hedge funds BMY owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.